 |
市場調查報告書
商品編碼
2077522
軟骨發育不全治療市場：依治療類型、給藥途徑、通路及地區分類Achondroplasia Treatment Market, By Treatment Type, By Route of Administration, By Distribution Channel, by Region |
||||||
軟骨發育不全治療市場預計在 2026 年達到 3.26 億美元，預計到 2033 年將達到 29.083 億美元。預計從 2026 年到 2033 年，該市場將以 36.7% 的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 3.26億美元 |
| 歷史數據時期： | 2020-2024 | 預測期： | 2026-2033 |
| 2026年至2033年預測期間的複合年成長率： | 36.70% | 2033年市場規模預測： | 29.083億美元 |
軟骨發育不全是一種以四肢短小為特徵的侏儒症。軟骨發育不全的特徵包括軀幹大小正常，四肢（特別是上臂和大腿）短小，手肘關節活動範圍受限以及頭部增大。脊椎狹窄是指脊椎腔變窄，可能壓迫脊髓上段，是軟骨發育不全的潛在嚴重併發症之一。脊椎狹窄的特徵是腿部疼痛、麻木和無力，並可能導致行走困難。軟骨發育不全是FGFR3基因突變引起的。 FGFR3基因在指導參與骨骼和腦組織發育和維持的蛋白質合成中發揮作用。
市場動態
預計在預測期內，軟骨發育不全治療藥物法規核准的增加將推動市場成長。例如，2021年11月，全球生物技術公司BioMarin宣布，美國食品藥物管理局（FDA）已加速批准其注射藥物VOXZOGO（vosolitide）用於促進5歲及以上骨骺未閉合的軟骨發育不全兒童的線性生長。此外，2021年8月，BridgeBio Pharma, Inc.的子公司QED Therapeutics宣布，其每日一次注射藥物VOXZOGO（vosolitide）已獲得歐盟委員會（EC）的上市許可，用於治療2歲至骨骺閉合（直至兒童青春期後達到最終成人身高）的兒童軟骨發育不全。
此外，領先企業活性化對軟骨發育不全治療藥物的研發投入，預計將在預測期內推動該治療領域的成長。例如，2021年11月，專注於適體療法的臨床階段製藥公司RIBOMIC, Inc.宣布了使用RBM-007治療軟骨發育不全的I期臨床試驗（受試者為健康志願者）結果。該試驗已於2021年5月完成。
本次測試的主要特點：
- 該研究揭示了各個細分市場的潛在商機，並為該市場說明了一個有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球軟骨發育不全治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份《全球軟骨發育不全治療市場》報告針對產業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球軟骨發育不全治療市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期新藥上市
- 流行病學
- 併購和合作
- 監管趨勢
- PEST分析
第4章：軟骨發育不全治療的全球市場。
- 經濟影響
- 對供需的影響
第5章 全球軟骨發育不全治療市場：依治療類型分類，2021-2033年
- 沃索利肽
- 人體生長荷爾蒙
- 其他
第6章 全球軟骨發育不全治療市場：依給藥途徑分類，2021-2033年
- 口服
- 腸外
第7章 全球軟骨發育不全治療市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球軟骨發育不全治療市場：依地區分類，2021-2033年
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東
- 非洲
第9章 競爭情勢
- 公司簡介
- BioMarin
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- LG Chem
- Ferring BV
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop BIoTech Co., Ltd.
第10章
- 參考
- 調查方法
Achondroplasia Treatment Market is estimated to be valued at USD 326.0 Mn in 2026 and is expected to reach USD 2,908.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 36.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 326.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 36.70% | 2033 Value Projection: | USD 2,908.3 Mn |
Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.
Market Dynamics
Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Achondroplasia Treatment market based on the following parameters- Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.
Detailed Segmentation:
- Global Achondroplasia Treatment Market, By Treatment Type (Revenue, USD Mn, 2021 - 2033)
- Vosoritide
- Human Growth Hormone
- Others
- Global Achondroplasia Treatment Market, By Route of Administration:
- Oral
- Parenteral
- Global Achondroplasia Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Achondroplasia Treatment, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- BioMarin
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- Hoffmann-La Roche Ltd
- LG Chem
- Ferring B.V.
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop Biotech Co., Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Achondroplasia Treatment Market,
- Economic Impact
- Impact on Supply and Demand
5. Global Achondroplasia Treatment Market, By Treatment Type, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Vosoritide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
6. Global Achondroplasia Treatment Market, By Route of Administration, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
7. Global Achondroplasia Treatment Market, By Distribution Channel, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
8. Global Achondroplasia Treatment Market, By Regions, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2021 €" 2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- BioMarin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RIBOMIC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ascendis Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BridgeBio Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PhaseBio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SiSaf
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F.Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- JCR Pharmaceuticals Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- KVK TECH, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- VIVUS LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ProLynx Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xiamen Amoytop Biotech Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BioMarin
10. Section
- References
- Research Methodology
- About us and Sales Contact
